Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2019 1
2020 5
2021 7
2022 2
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Bannoura SF, et al. Among authors: al hallak mn. Cancer Metastasis Rev. 2021 Sep;40(3):819-835. doi: 10.1007/s10555-021-09990-2. Epub 2021 Sep 9. Cancer Metastasis Rev. 2021. PMID: 34499267 Free PMC article. Review.
Gastrointestinal stromal tumor: a review of current and emerging therapies.
Al-Share B, Alloghbi A, Al Hallak MN, Uddin H, Azmi A, Mohammad RM, Kim SH, Shields AF, Philip PA. Al-Share B, et al. Among authors: al hallak mn. Cancer Metastasis Rev. 2021 Jun;40(2):625-641. doi: 10.1007/s10555-021-09961-7. Epub 2021 Apr 19. Cancer Metastasis Rev. 2021. PMID: 33876372 Review.
Gastric Cancer Heterogeneity and Clinical Outcomes.
Sexton RE, Hallak MNA, Uddin MH, Diab M, Azmi AS. Sexton RE, et al. Among authors: hallak mna. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820935477. doi: 10.1177/1533033820935477. Technol Cancer Res Treat. 2020. PMID: 32799763 Free PMC article.
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. Khan HY, et al. Among authors: al hallak mn. Cancer Res Commun. 2022 May;2(5):342-352. doi: 10.1158/2767-9764.crc-21-0176. Epub 2022 May 10. Cancer Res Commun. 2022. PMID: 35573474 Free PMC article.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. Kim DW, et al. Among authors: al hallak mn. Future Oncol. 2024 Feb 13. doi: 10.2217/fon-2023-0824. Online ahead of print. Future Oncol. 2024. PMID: 38348690 Free article. Review.
22 results